v1a

LIT-001 improves social interaction in a mouse model of autism.It is the first nonpeptide oxytocin receptor agonist with EC50 of 55 nM and Ki of 226 nM.

Xanthone V1a is a useful organic compound for research related to life sciences and the catalog number is T126501.

V1a V2 antagonist 1 (Compound 18j) is an orally active dual-target antagonist of V1a and V2 receptors, exhibiting high binding affinity toward these receptors [Ki values are hV1a: 0.13 nM, hV2: 0.53 nM, and mV1a: 0.5 nM; IC50 for hV1a is 2.2 nM]. This compound can inhibit oxytocin-induced scratching behavior in mice.

ω-Hexatoxin-Hv1a, a neurotoxin extracted from the venom of the spider Hadronyche versuta, inhibits voltage-gated calcium channels [1] [2].

OPC-51803 is an orally available nonapeptidylpressor (AVP) V(2) receptor selective agonist for the treatment of urinary incontinence and nocturia.

PF-184563 is an effective and selective non-peptide antagonist of the V1a receptor with oral activity, suitable for studying Raynaud's disease and dysmenorrhoea.

RG7713 (RO 5028442) has been used in trials studying Autistic Disorder.

Balovaptan (RG7314) is a highly potent and selective brain-penetrant vasopressin 1a (hV1a) receptor antagonist, with Kis of 1 and 39 nM for human (hV1a) and mouse (mV1a) receptors. It is used for the research of autism.

L-371,257 is a competitive antagonist of oxytocin receptor with pA2 of 8.4 and Ki of 19 nM. L-371,257 shows a Ki of 3.7 nM for vasopressin receptor 1a.

SRX246 has no interaction at V1b and V2 receptors. SRX246 shows negligible binding at 64 other receptors classes, including 35 G-proteincoupled receptors. SRX246 is a potent and CNS-penetrant vasopressin 1a (V1a) receptor antagonist (Ki=0.3 nM for human V

VNA-932 is an agonist of the vasopressin V2-receptor (IC50: 80.3 nM and 778 nM in human-V2 binding and V1a binding assay).

OT-R agonist 1 TFA (compound 5) is an oxytocin receptor (OT-R) agonist with an EC50 value of 0.39 nM. It exhibits V1A antagonist activity, with an EC50 value of 2432 nM, and can be utilized in studies related to central nervous system diseases.

Conivaptan, a non-peptide inhibitor of antidiuretic hormone, was approved for hyponatremia caused by the syndrome of inappropriate antidiuretic hormone (SIADH), there is also some evidence that it may be effective in heart failure. Conivaptan inhibits sub

vasopressin V1A receptor antagonist

oxytocin receptor partial agonist

L-368899 is a non-peptide and orally active antagonist of oxytocin receptor (IC50: 8.9 nM). It displays 40-fold selectivity over vasopressin V1a and V2 receptors (IC50: 370 and 570 nM respectively).

Khusimol is a vasopressin V1a receptors non-peptide ligand that acts by inhibiting the binding of vasopressin.

RWJ 676070 is an antagonist of vasopressin V1A/V2 receptor.

Selepressin, an analog of vasopressin, is a potent, selective vasopressin V1a receptor agonist.

SRX 251, a vasopressin V1a receptor antagonist, is used potentially for the treatment of primary dysmenorrhea.

YM 218 is a novel, potent, selective antagonist of nonpeptide vasopressin V1A receptor.

YM 471 is a non-peptide arginine vasopressin (AVP) V1A and V2 receptor antagonist with oral activity.

Conivaptan hydrochloride (Vaprisol) is an orally active vasopressin V2 and V1A receptor antagonist, used in the therapy of hypervolemic hyponatremia and euvolemic.

Pecavaptan is a vasopressin receptor antagonist.